Population-level Epidemiological Trends In Hepatocellular Carcinoma In Queensland 1996 - 2010.
Funder
National Health and Medical Research Council
Funding Amount
$251,695.00
Summary
Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC t ....Incidence and mortality of hepatocellular carcinoma (HCC, the most common form of liver cancer) is increasing in Australia, driven by viral hepatitis infections. Disease burden is not defined in Queensland, particularly for Indigenous, migrant and regional and remote communities. Such factors may influence risk of viral hepatitis, access to treatment, and incidence and survival of HCC. Defining disease burdens will enable clinical programs targeted at groups most at risk in order to impact HCC trends.Read moreRead less
Deadly Liver Mob: Engaging Aboriginal People In Viral Hepatitis, HIV And Sexual Health Services
Funder
National Health and Medical Research Council
Funding Amount
$848,441.00
Summary
Rates of blood-borne viruses and sexually transmissible infections are high among the Aboriginal and Torres Strait Islander population. A local initiative in western Sydney has trialed a new approach to engagement and care of Aboriginal people. We will implement this approach in services across NSW and evaluate its effectiveness as a sustainable and acceptable model for engaging Aboriginal people in care and develop an implementation plan for future roll-out to other services.
Eliminating Hepatitis C Transmission By Enhancing Hepatitis C Care And Treatment In Primary Health Care Settings.
Funder
National Health and Medical Research Council
Funding Amount
$1,221,831.00
Summary
In developed countries, people who inject drugs (PWID) are the group at greatest risk of hepatitis C (HCV) infection but few PWID receive HCV treatment. With the advent of highly effective non-interferon based treatments HCV elimination, although ambitious, is now being seriously considered globally. This partnership grant will explore the feasibility of eliminating HCV transmission by enhancing HCV care and treatment for PWID in primary health care settings.
SCALE-C: Strategies For Hepatitis C Testing And Treatment In Aboriginal Communities That Lead To Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,175,170.00
Summary
Prevalence of hepatitis C infection within the Aboriginal population is among the highest of any identifiable population in Australia. Highly effective, direct-acting antiviral (DAA) therapy, and their listing on the PBS in 2016 has revolutionised HCV clinical management in Australia. The SCALE-C study will evaluate an established test and treat model to rapidly scale-up DAA within four Aboriginal communities to determine both impact on community prevalence and ongoing transmission.
Individualising Care For Patients With Chronic Hepatitis C: Predicting Side Effects And Treatment Response Using Genomic And Proteomic Approaches.
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially impro ....Patients undergoing treatment for hepatitis C must endure a treatment characterized by unpredictable treatment side effects and uncertainty about the likelihood of cure. This project will investigate genetic predictors of treatment related side-effects and protein markers to predict treatment response. Better definition of the risks and benefits of therapy, may facilitate patients and clinicians to make more informed decisions about treatment, thus individualising treatment and potentially improving the safety and efficacy of therapy.Read moreRead less
Some patients with chronic disease struggle to look after their condition at home. An educational approach called teach-back has been shown to improve people’s understanding of how to manage their condition. Teach-back is not commonly used in Australia, but is recommended by key policy documents. This project will develop and test a process for integrating teach-back into pre-discharge care of hospital patients with chronic conditions, by training nurses to act as teach-back mentors.
A Pragmatic Randomised Clinical Trial Of Nicotine Vaporisers Added To Smoking Cessation Treatment For Priority Populations Living With Comorbidities
Funder
National Health and Medical Research Council
Funding Amount
$1,499,145.00
Summary
Smoking is a leading cause of early death for people with certain health conditions because they are more likely to smoke and are also at greater risk of tobacco-related disease. This clinical trial will test whether encouraging people living with Hepatitis C Virus, people on opiate substitution therapy and people living with HIV who smoke to use nicotine vaporisers long-term, in addition to current smoking cessation treatments, will help them to stay abstinent from smoking.
InterLACE: International Collaboration For A Life Course Approach To Reproductive Health And Chronic Disease Events
Funder
National Health and Medical Research Council
Funding Amount
$495,965.00
Summary
Cardiovascular disease and diabetes are major chronic diseases among women. This world-leading research combines data from 7 international and 3 Australian studies of womenÍs health. We will investigate the relationship of reproductive health, from menarche to menopause, with the risk of Type 2 diabetes and cardiovascular disease in later life. Findings will support the development of policies and preventive health strategies to reduce the risk of these chronic diseases.
The Analgesic Evaluation Of Novel Natural Products From The Australian Plant Barringtonia Acutangula
Funder
National Health and Medical Research Council
Funding Amount
$174,500.00
Summary
This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that wi ....This project aims to evaluate the analgesic activity of several novel natural products that have been isolated from the Australian plant Barringtonia acutangula. An Australian Aboriginal tribe have been known to use B. acutangula aqueous bark extracts for its analgesic properties. Griffith University researchers have confirmed this biological activity in the crude aqueous bark extract. A large scale extraction and isolation process will obtain the novel compounds in sufficient quantities that will allow for their pharmacological evaluation as potential analgesic drugs.Read moreRead less